CAS No.99291-20-0 | V-9-M cholecystokinin nonapeptide
CAS No.99291-20-0 | V-9-M cholecystokinin nonapeptide
CAS No.99291-20-0 | V-9-M cholecystokinin nonapeptide
CAS No.99291-20-0 | V-9-M cholecystokinin nonapeptide
+
  • CAS No.99291-20-0 | V-9-M cholecystokinin nonapeptide
  • CAS No.99291-20-0 | V-9-M cholecystokinin nonapeptide
  • CAS No.99291-20-0 | V-9-M cholecystokinin nonapeptide
  • CAS No.99291-20-0 | V-9-M cholecystokinin nonapeptide

CAS No.99291-20-0 | V-9-M cholecystokinin nonapeptide

Name: V-9-M cholecystokinin nonapeptide CAS No.99291-20-0 MF:C42H69N9O14S MW:956.11 Purity:97% Package: 1g,5g,25g,100g,500g Worldwide Delivery

Categories:

Biochemicals

Product introduction

Introduction and application of  CAS No.99291-20-0 | V-9-M cholecystokinin nonapeptide

 

Synonyms:L-Methionine,L-valyl-L-prolyl-L-valyl-L-a-glutamyl-L-alanyl-L-valyl-L-a-aspartyl-L-prolyl-

Cholecystokinin Precursor (24-32) (rat) H-Val-Pro-Val-Glu-Ala-Val-Asp-Pro-Met-OH

 

Specification:

ITEMS

SPECIFICATION

CAS

99291-20-0

MF

C42H69N9O14S

MW

956.11

Boiling Point

1350.7±65.0 °C

Density

1.306±0.06 g/cm3

Acidity coefficient

3.51±0.10

 

Semaglutide is a glucagon-like peptide receptor agonist, that is, a GLP-1 receptor agonist. Human GLP-1 is a peptide hormone secreted by intestinal L cells.

 

Mechanism:

Its mechanism of action is to act on pancreatic islet beta cells, promote the synthesis and secretion of insulin, stimulate the proliferation and differentiation of pancreatic islet beta cells, inhibit the apoptosis of pancreatic islet beta cells, increase the number of pancreatic islet beta cells, and protect the pancreatic islet function. It can also act on pancreatic islet α cells, inhibit the release of glucagon and reduce the release of glycogen. Acts on pancreatic islet δ cells, promotes the secretion of somatostatin, and participates in inhibiting the secretion of glucagon. Enhance insulin sensitivity, slow down gastric emptying, act on the hypothalamus to suppress appetite, reduce weight, and achieve the effect of lowering blood sugar through these effects.

 

Application:

Semaglutide belongs to the glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) class of hypoglycemic drugs. This drug increases insulin secretion and inhibits glucagon secretion in a glucose-dependent manner. , and can promote gastric emptying, centrally suppress appetite, reduce food intake, thereby reducing glucose absorption and lowering blood sugar.

 

Package and transportation :

Package: 1g,5g,25g,100g,500g

Transportation: by courier/ by air/ by sea

Key words:

Related Products

Related Products

Inquiry

SUBMIT